Lunit, a global leader in AI for cancer diagnostics and precision oncology, has entered a strategic partnership with Labcorp, a major provider of laboratory services, to accelerate the real-world application of AI-driven digital pathology in oncology research. The collaboration will harness Labcorp’s deep clinical and pathology infrastructure alongside Lunit’s sophisticated AI algorithms to analyze tumor microenvironments at high resolution and derive clinically meaningful insights.

In the first phase of their work, both companies presented breakthroughs at the Society for Immunotherapy of Cancer (SITC) and the Association for Molecular Pathology (AMP) conferences. Using Lunit’s SCOPE IO® AI tool, researchers analyzed over 370 whole-slide images from NSCLC tumors with MET exon 14 skipping mutations, uncovering distinct immune phenotypes.  These AI-defined subtypes were further validated with immune gene-expression data, which confirmed expression pathways tied to inflamed or desert immune contexts. 

Labcorp’s oncology and pathology teams emphasized that such AI-enabled spatial profiling could redefine how biomarkers are discovered and developed. According to Shakti Ramkissoon, M.D., Ph.D., Vice President and Medical Lead for Oncology at Labcorp, the collaboration lays a foundation for more personalized cancer care using digital pathology to reveal patterns in tumors that were previously hidden to the human eye. 

Looking ahead, Lunit and Labcorp plan to scale the collaboration across more cancer types and genomic contexts. By combining AI with high-resolution imaging, the duo aims to accelerate biomarker discovery, deepen insights into tumor-immune interactions, and ultimately support more effective, tailored treatment strategies in precision oncology.